Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.


TSX:APLI - Post by User

Bullboard Posts
Post by mattusvion Jun 15, 2020 10:12am
164 Views
Post# 31150755

Indigenous Services eyeing Canadian trial of antiviral drug

Indigenous Services eyeing Canadian trial of antiviral drug
https://www.cbc.ca/news/indigenous/drug-department-trial-1.5610093

Indigenous Services Canada is watching for the results of the world's first trial to determine whether an antiviral medication developed in Japan could be used to prevent COVID-19, according to a letter provided to CBC News.

The potential of favipiravir, which received clearance from Health Canada for trial on May 18, has the attention of the department's First Nation and Inuit Health Branch (FNIHB), according to the letter written by a senior federal official.

Bullboard Posts